Onyx BiotecNSE:ONYX 13 EBITDA Margin % is 7.62% as of Mar. 2026, which is 41% below its 10-year median of 12.83. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Onyx Biotec ranks worse than 53.8% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Onyx Biotec's EBITDA for the
six
months ended in Mar. 2026 was ₹26.6 Mil. Onyx Biotec's Revenue for the
six
months ended in Mar. 2026 was ₹348.8 Mil. Therefore, Onyx Biotec's EBITDA margin for the quarter that ended in Mar. 2026 was 7.62%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Onyx Biotec EBITDA Margin % Related Terms
Onyx Biotec EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Onyx Biotec's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONYX vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Onyx Biotec's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Biotec EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Onyx Biotec's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onyx Biotec (NSE:ONYX) has a EBITDA Margin % of 7.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Onyx Biotec and its competitors. This is 41% below median its historical median of 12.83. Over the past decade, Onyx Biotec's EBITDA Margin % has ranged from 5.53 to 18.58. According to the industry distribution chart, Onyx Biotec ranks #439 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 53.8%.
Is Onyx Biotec's EBITDA Margin % too high?
Onyx Biotec's current EBITDA Margin % of 7.62% is 41% below median its 10-year median of 12.83. Over the past 10 years, this metric has ranged from a low of 5.53 to a high of 18.58. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Onyx Biotec's value of 7.62% is 1.9% above this industry median. Based on the distribution chart, Onyx Biotec ranks #439 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Onyx Biotec ranks #439 out of 816 companies for EBITDA Margin %. This places Onyx Biotec in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Onyx Biotec's value of 7.62% is 1.9% above this benchmark. Historically, Onyx Biotec's own EBITDA Margin % has ranged from 5.53 to 18.58 over the past decade. While the company's 10-year median is 12.83 vs. the industry median of 7.48, Onyx Biotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Biotec's current EBITDA Margin % of 7.62% is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Onyx Biotec and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Biotec's current EBITDA Margin % is 7.62%, which is 41% below median its own 10-year median of 12.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current EBITDA Margin % of 7.62%. The current EBITDA Margin % is 7.62%, which is 41% below median its 10-year median of 12.83 and 1.9% above the Medical Devices & Instruments industry median of 7.48. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current EBITDA Margin % is 7.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score
Get the complete analysis for NSE:ONYX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONYX has been successfully added to your 